Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR-PATH
2024-513363-15-01Phase 4Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of clopidogrel and aspirin in arteriosclerosis obliterans (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Composite of all-cause death and cardiovascular adverse events at 1 year. Planned start Jul 2024; status: authorised.
02
Drugs
clopidogrelaspirin
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on 2024-513363-15-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513363-15-01.